Lauren Averett Byers, MD, on the Identification of SCLC Subtypes

Video

The associate professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center indicated that these data provide the first avenue for personalized treatment of small cell lung cancer.

Using tumor expression data and non-negative matrix factorization, investigators at The University of Texas MD Anderson Cancer Center were able identify 4 subtypes of small cell lung cancer (SCLC).

The study results, published in Cancer Cell, led investigators to propose that matching baseline tumor subtype to therapy, as well as manipulating subtype switching on therapy, could possibly enhance depth and duration of response for patients with SCLC.

According to senior author Lauren Averett Byers, MD, associate professor of Thoracic/Head & Neck Medical Oncology at MD Anderson, these data provide the first avenue for personalized treatment of SCLC.

In an interview with CancerNetwork®, Byers further explained the significance of this study and what she hopes practicing oncologists will take away from these findings.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Reference:

Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. Published online January 21, 2021. doi: 10.1016/j.ccell.2020.12.014

Recent Videos
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
CAR T-cell therapies or other agents that impact the immune system in the long term may be important to keep in mind for the management of SCLC.
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.
Related Content
Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Russ Conroy
October 18th 2025
Article

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Those who had elevated ProGRP at baseline and normalized ProGRP following chemoradiotherapy achieved a median PFS of 49.3 months vs 7.8 months in those who had persistently elevated ProGRP.

Progastrin-Releasing Peptide Levels Correlate With OS and PFS in LS-SCLC

Tim Cortese
October 4th 2025
Article

Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
March 24th 2025
Podcast

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC

Russ Conroy
October 2nd 2025
Article

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

CRS onset typically occurred within 12 hours after tarlatamab infusion and was resolved with antipyretics for fever and intravenous fluids.

Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC

Tim Cortese
October 2nd 2025
Article

A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.